viewScancell Holdings PLC

Scancell signs second AvidiMab collaboration, this time in China

This is the company's second research agreement, following the first in September

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) has signed a second collaboration and non-exclusive research agreement, this time with a Chinese biotechnology company.

The collaboration will see the Chinese partner conduct pre-clinical studies to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) that have been enhanced with the AIM-listed company's AvidiMab technology, for the treatment of cancer.

READ: Scancell hails first antibody collaboration deal

Scancell agreed a first collaboration agreement for AvidiMab in September, alongside a pipeline of TaG mAbs, with a leading antibody technology company.

The mAbs turned out by AvidiMab are different to those used successfully in other targeted cancer treatments as they target tumour-associated glycans that are associated with malignancies, with AvidiMab enhancing the ability of these mAbs to hone in on TaGs.

"As previously stated, we believe our novel AvidiMab platform and tumour associated glycan antibodies have broad partnering potential and this has been further demonstrated by today's agreement, the second in four months," said Cliff Holloway, Scancell's chief executive officer. 

"This is our first collaboration in China, and we look forward to updating the market on further progress with this platform in due course."

Quick facts: Scancell Holdings PLC

Price: 11.625 GBX

Market: LSE
Market Cap: £94.77 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


2 min read